Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
11C-ER176 PET Imaging in Diabetic Gastroparesis
NCT04762719Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of [11C]ER176 in diabetic gastroparesis (3 arms), sponsored by Mayo Clinic. Primary endpoint: Uptake of 11C-ER 176 in the Stomach Muscle. Started May 2021; status: completed.
02
Drugs
[11C]ER176
03
Conditions
diabetic gastroparesis
Beyond the preview
Go deeper on NCT04762719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762719.